A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

332

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Non-small Cell Lung CancerNasopharyngeal CarcinomaSolid Tumor

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

PD-1 Monoclonal Antibody

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY